WHAT IS CLAIMED IS:

1. A compound having formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

the subscript n is 1 or 2;

each R^1 is a member selected from the group consisting of fluoro, chloro, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkoxy, and C_2-C_4 alkynyl;

wherein at least one R^1 is fluoro; and

one of R^{2a} and R^{2b} is fluoro and the other of R^{2a} and R^{2b} is H.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{2a} is fluoro and R^{2b} is H, or wherein R^{2a} is H and R^{2b} is fluoro.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{2a} is fluoro, and n is 1.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{2a} is fluoro, and n is 2.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{2b} is fluoro, and n is 1.

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{2b} is fluoro, and n is 2.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 1.

8. The compound of claim 1, having the formula:



(Ia) ,

or pharmaceutically acceptable salt thereof, wherein the subscript n is 1.

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof wherein n is 1, and having the formula:



(Ib) ,

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

n is 2,

one R^1 is fluoro, and

the other may be selected from the group consisting of fluoro, C_1-C_4 alkyl, C_{1-4} alkoxy and C_2-C_4 alkynyl.

11. The compound of claim 1, wherein n is 2, and having the formula:



(Ic) ,

or pharmaceutically acceptable salt thereof.

12. The compound of claim 1, having the formula



(Id) ,

or a pharmaceutically acceptable salt thereof, wherein

R^1 may be selected from the group consisting of fluoro, C_1-C_4 alkyl, C_1-C_4 alkoxy, and C_2-C_4 alkynyl.

13. A compound selected from the group consisting of:

















, and

,

or pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

15. Use of a compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating hypertrophic cardiomyopathy (HCM), wherein an effective amount of the compound or pharmaceutically acceptable salt thereof is to be administered to a subject in need thereof.

16. Use of a compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating left ventricular hypertrophy, wherein an effective amount of the compound or pharmaceutically acceptable salt thereof is to be administered to a subject in need thereof.

17. Use of a compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating hypertrophic cardiomyopathy (HCM), wherein an effective amount of the compound or pharmaceutically acceptable salt thereof is to be administered to a subject in need thereof, in conjunction with one or more therapies selected from the group consisting of an aldosterone receptor antagonist, an angiotension-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker, a beta-blocker, a neural endopeptidase inhibitor, a positive inotropic agent, a diuretic, and a vasodilator.

18. Use of a compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a cardiac disease or disorder, wherein an effective

amount of the compound or pharmaceutically acceptable salt thereof is to be administered to a subject in need thereof,

wherein the cardiac disease or disorder is selected from the group consisting of diastolic dysfunction, diastolic heart failure, valvular disease, aortic stenosis, restrictive cardiomyopathy, inflammatory cardiomyopathy, Loeffler endocarditis, endomyocardial fibrosis, infiltrative cardiomyopathy, hemochromatosis, Fabry disease, glycogen storage disease, congenital heart disease, tetralogy of Fallot, and angina pectoris.

19. The use of claim 17, wherein the positive inotropic agent is dobutamine or milnirone.

20. The use of claim 17, wherein the diuretic is furosemide.

21. The use of claim 17, wherein the vasodilator is selected from the group consisting of a calcium channel blocker, an endothelin receptor antagonist, a phosphodiesterase inhibitor, a renin inhibitor, and a smooth muscle modulator.

22. The use of claim 16, in conjunction with a therapy selected from the group consisting of valve repair, valve replacement, and effective antihypertensive therapy.

23. The use of claim 22, wherein the subject has a disease or disorder selected from the group consisting of chronic mitral regurgitation, chronic aortic stenosis, and chronic systemic hypertension.

24. The use of claim 18, wherein the diastolic heart failure is heart failure with preserved ejection fraction (HFpEF).

25. The use of claim 15, wherein the HCM is obstructive hypertrophic cardiomyopathy (oHCM).

26. The use of claim 15, wherein the HCM is non-obstructive hypertrophic cardiomyopathy (nHCM).

27. A compound, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

28. The compound of claim 27, wherein the compound is:



.

29. Use of a compound in claim 27, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating hypertrophic cardiomyopathy (HCM) in a subject in need thereof, wherein a pharmaceutically effective amount of the compound or pharmaceutically acceptable salt thereof is to be administered to the subject.

30. The use of claim 29, wherein the HCM is obstructive hypertrophic cardiomyopathy (oHCM).

31. The use of claim 29, wherein the HCM is non-obstructive hypertrophic cardiomyopathy (nHCM).

32. Use of a compound in claim 28, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating hypertrophic cardiomyopathy (HCM) in a subject in need thereof, wherein a pharmaceutically effective amount of the compound or pharmaceutically acceptable salt thereof is be administered to the subject.

33. The use of claim 32, wherein the HCM is obstructive hypertrophic cardiomyopathy (oHCM).

34. The use of claim 32, wherein the HCM is non-obstructive hypertrophic cardiomyopathy (nHCM).

35. Use of a compound in claim 27, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating heart failure with preserved ejection fraction (HFpEF) in a subject in need thereof, wherein a pharmaceutically effective amount of the compound or pharmaceutically acceptable salt thereof is be administered to the subject.

36. Use of a compound in claim 28, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating heart failure with preserved ejection fraction (HFpEF) in a subject in need thereof, wherein a pharmaceutically effective amount of the compound or pharmaceutically acceptable salt thereof is be administered to the subject.

37. Use of a compound in claim 27, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating left ventricular hypertrophy in a subject in need thereof, wherein a pharmaceutically effective amount of the compound or pharmaceutically acceptable salt thereof is be administered to the subject.

38. Use of a compound in claim 28, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating left ventricular hypertrophy in a subject in need thereof, wherein a pharmaceutically effective amount of the compound or pharmaceutically acceptable salt thereof is be administered to the subject.

39. A pharmaceutical composition comprising a compound of claim 27, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

40. A pharmaceutical composition comprising a compound of claim 28, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.